Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/133123
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer |
Author: | Brunton, H. Caligiuri, G. Cunningham, R. Upstill-Goddard, R. Bailey, U.M. Garner, I.M. Nourse, C. Dreyer, S. Jones, M. Moran-Jones, K. Wright, D.W. Paulus-Hock, V. Nixon, C. Thomson, G. Jamieson, N.B. McGregor, G.A. Evers, L. McKay, C.J. Gulati, A. Brough, R. et al. |
Citation: | Cell Reports, 2020; 31(6):1-28 |
Publisher: | Elsevier |
Issue Date: | 2020 |
ISSN: | 2211-1247 2211-1247 |
Statement of Responsibility: | Holly Brunton, Giuseppina Caligiuri, Richard Cunningham, Rosie Upstill-Goddard, Ulla-Maja Bailey, Ian M.Garner ... et al. |
Abstract: | Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lineages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by distinct metabolic phenotypes. Loss of genes that drive endodermal lineage specification, HNF4A and GATA6, switch metabolic profiles from classical (pancreatic) to predominantly squamous, with glycogen synthase kinase 3 beta (GSK3β) a key regulator of glycolysis. Pharmacological inhibition of GSK3β results in selective sensitivity in the squamous subtype; however, a subset of these squamous patient-derived cell lines (PDCLs) acquires rapid drug tolerance. Using chromatin accessibility maps, we demonstrate that the squamous subtype can be further classified using chromatin accessibility to predict responsiveness and tolerance to GSK3β inhibitors. Our findings demonstrate that distinct patterns of chromatin accessibility can be used to identify patient subgroups that are indistinguishable by gene expression profiles, highlighting the utility of chromatin-based biomarkers for patient selection in the treatment of PDAC. |
Keywords: | PDAC subtypes; HNF4A; GATA6; metabolic targeting; GSK3B; intronic and distal promoters; chromatin landscapes; therapeutic tolerance |
Rights: | © 2020 The Author(s). |
DOI: | 10.1016/j.celrep.2020.107625 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/631701 http://purl.org/au-research/grants/nhmrc/427601 http://purl.org/au-research/grants/nhmrc/535903 http://purl.org/au-research/grants/nhmrc/1162860 http://purl.org/au-research/grants/nhmrc/1162556 |
Published version: | http://dx.doi.org/10.1016/j.celrep.2020.107625 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.